Cision Wire http://www.cisionwire.com Cision is the leading global provider of media research, distribution, monitoring and evaluation services. With over 40 locations throughout the world, Cision provides the insight, expertise and intelligence that improve performance and build reputations. Fri, 10 Feb 2012 12:15:04 GMT Cision Wire 120 32 http://www.cisionwire.com http://www.cisionwire.com/images/CisionLogoSmall.gif FURTHER STUDIES MAY BE REQUIRED FOR MOB-015 http://www.cisionwire.com/moberg-derma-ab/r/further-studies-may-be-required-for-mob-015,c9218148 cision449778

Moberg Derma AB (OMX: MOB) has analysed data from approximately fifty per cent of the patients in the ongoing open phase II study for MOB-015. Based on the analysis, the company assesses that there is low probability that the final results from the study will be sufficient for out-licensing the project. Further studies will probably be required before continuing to phase III. The ongoing phase II study will be completed and results are expected by the end of the year.

]]> Thu, 09 Feb 2012 06:59:00 GMT MOBERG DERMA STRENGTHENS MANAGEMENT TEAM http://www.cisionwire.com/moberg-derma-ab/r/moberg-derma-strengthens-management-team,c9207774 cision439697 Moberg Derma AB (STO: MOB) has hired Lena Pereswetoff-Morath as Vice President Pharmaceutical Innovation & Development. Lena comes from a similar position at Orexo and has extensive experience in drug development, e.g. from Biolipox and AstraZeneca.

]]> Tue, 17 Jan 2012 08:30:00 GMT MOBERG DERMA TERMINATES COLLABORATION IN CANADA http://www.cisionwire.com/moberg-derma-ab/r/moberg-derma-terminates-collaboration-in-canada,c9202488 cision433713

Moberg Derma AB (STO: MOB) and Medical Futures Inc. have agreed that the distribution agreement between the parties shall cease, and that cooperation ends. The agreement gave the distributor the exclusive right to market and sell Emtrix® in Canada.

]]> Thu, 22 Dec 2011 14:00:00 GMT MOBERG DERMA AND MENARINI GROUP SIGN AGREEMENT FOR EMTRIX IN ITALY http://www.cisionwire.com/moberg-derma-ab/r/moberg-derma-and-menarini-group-sign-agreement-for-emtrix-in-italy,c9197979 cision428233

Moberg Derma AB (STO: MOB) has entered into a distribution agreement with Menarini Group for Emtrix® – for discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement Menarini’s OTC Division is granted exclusive rights to market and sell Emtrix® in Italy under the trademark YouDerm Emtrix®.

]]> Fri, 09 Dec 2011 07:00:00 GMT MOBERG DERMA AND MEDA EXTEND LICENSE AGREEMENT http://www.cisionwire.com/moberg-derma-ab/r/moberg-derma-and-meda-extend-license-agreement,c9193731 cision424311

Moberg Derma AB (publ.) and Meda have entered into an additional license agreement for Nalox™ - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. The agreement extends Meda's rights to market and sell Nalox™ to Russia, Turkey and several countries in Eastern Europe. Moberg Derma assumes production and supply responsibility.

]]> Wed, 30 Nov 2011 13:00:00 GMT MOBERG DERMA IS GRANTED MSEK 4 FOR LIMTOP http://www.cisionwire.com/moberg-derma-ab/r/moberg-derma-is-granted-msek-4-for-limtop,c9187108 cision417572 Moberg Derma AB (OMX: MOB) has been granted 4 MSEK by Vinnova for the development of Limtop, an innovative formulation for the treatment of actinic keratosis, genital warts and basal cell cancer. The goal of the Vinnova funding is that small and medium-sized enterprises will increase their competitiveness and growth by investing in research and development and thus contribute to growth in Sweden.

]]> Tue, 15 Nov 2011 11:00:00 GMT MOBERG DERMA DISCONTINUES PRECLINICAL DEVELOPMENT PROGRAM FOR A-FIZZ http://www.cisionwire.com/moberg-derma-ab/r/moberg-derma-discontinues-preclinical-development-program-for-a-fizz,c9179619 cision410723

Moberg Derma AB (OMX: MOB) has decided to discontinue the preclinical program for the drug candidate for treatment of anal fissures - A-Fizz. The decision to discontinue was made since the validating preclinical results did not fulfill the company’s criteria.

]]> Thu, 27 Oct 2011 14:00:00 GMT MOBERG DERMA NOMINATION COMMITTEE APPOINTED http://www.cisionwire.com/moberg-derma-ab/r/moberg-derma-nomination-committee-appointed,c9177075 cision408252

In accordance with the decision taken at Moberg Derma’s Annual General Meeting 2011 the Chairman of the Board has contacted the largest shareholders of the company to appoint a Nomination Committee before the Annual General Meeting 2012.

]]> Fri, 21 Oct 2011 11:00:00 GMT MOBERG DERMA AND MEDA SIGN AGREEMENT FOR NALOX IN EUROPE http://www.cisionwire.com/moberg-derma-ab/r/moberg-derma-and-meda-sign-agreement-for-nalox-in-europe,c9162768 cision394270

Moberg Derma AB (OMX: MOB) and Meda AB have entered into a license agreement covering rights for Nalox® - Moberg Derma’s patented product for the treatment of discolored and damaged nails caused by nail fungus (onychomycosis) or nail psoriasis. Under the agreement, Meda is granted exclusive rights to market and sell Nalox® in a large number of countries in Europe. Moberg Derma assumes production and supply responsibility. Over the past year, Meda has made Nalox® market leader in the Nordic region.

]]> Mon, 19 Sep 2011 06:00:00 GMT MOBERG DERMA HAS COMPLETED RECRUITMENT FOR MOB-015 PHASE II CLINICAL STUDY http://www.cisionwire.com/moberg-derma-ab/r/moberg-derma-has-completed-recruitment-for-mob-015-phase-ii-clinical-study,c9160165 cision391543 Moberg Derma AB (OMX: MOB) has successfully completed the recruitment of 237 patients with nail fungus (onychomycosis) to participate in the ongoing MOB-015 phase II study. MOB-015 is the company’s second-generation topical treatment for nail fungus.

]]> Mon, 12 Sep 2011 06:30:00 GMT